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The number of patients with atrial fibrillation and congestive heart failure has steadily increased in the
United States. The presence of atrial fibrillation increases morbidity and mortality for patients with left
ventricular dysfunction. The emergence of cardiac resynchronization therapy to improve symptoms
and survival from congestive heart failure may provide benefits for those with atrial fibrillation; we
review the pathophysiology of atrial fibrillation in the presence of left ventricular dysfunction and
the promise of cardiac resynchronization therapy to improve symptoms for the for these patients.
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Atrial fibrillation in the patient with left ventricu-
lar dysfunction presents unique challenges to the
physician and patient. The emergence of cardiac
resynchronization therapy, or CRT, through biven-
tricular pacing has been an important advance in
the management of congestive heart failure, and
recent studies have demonstrated improved qual-
ity of life and survival benefit that will certainly
expand its use.
The role of CRT in patients with atrial fibrillation
and congestive heart failure is not as well estab-
lished as for those in sinus rhythm. We will review
mechanisms of the mutually detrimental effects of
atrial fibrillation and congestive heart failure, their
impact on morbidity and mortality, and the physi-
ologic concepts that could form the basis for using





Atrial fibrillation affects approximately 2 million
people in the United States, making it the most com-
mon cause of hospitalization for cardiac arrhyth-
mias in the United States.1 Congestive heart fail-
ure affects approximately 5 million people in the
United States2 with an incidence that has risen by
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155% over the past 20 years. Currently, the preva-
lence of atrial fibrillation ranges from 1 percent
to those under 50 years of age to approximately
9% in those over 80 years of age. An analysis of a
national hospital admissions records from 1996 to
2001 showed that primary admission for atrial fib-
rillation accounted for 1% of all admissions, with
admissions increasing 34% over this study period.3
Like other forms of heart disease, more men than
women develop atrial fibrillation at a younger age,
but the incidence for women approaches that of
men in older populations. Congestive heart failure
is listed as a secondary diagnosis in 22% of admis-
sions for atrial fibrillation, second only to hyperten-
sion. Conversely, for patients with atrial fibrillation
as a secondary diagnosis, congestive heart failure is
listed as the most common primary diagnosis across
all age groups.4
Congestive heart failure and atrial fibrillation
have a mutually adverse effect on mortality and
morbidity. Data from the Framingham population
show that patients with congestive heart failure
that go on to develop atrial fibrillation have almost
twice the mortality rate as those with a normal
rhythm.5
Based on these findings, it stands to reason that
restoration of sinus rhythm in patients with conges-
tive heart failure would have beneficial effects not
only on quality of life but survival as well. Unfor-
tunately, previous attempts to use antiarrhythmic
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drugs to maintain sinus rhythm were unsuccessful
or associated with increased mortality from proar-
rhythmia. In a subset analysis of the CHF-STAT
trial, patients treated with amiodarone that spon-
taneously converted to sinus rhythm had a higher
survival rate than those who did not convert.6 Non-
pharmacologic approaches have been used to re-
store and maintain sinus rhythm as well. Hsu and
others found that patients with congestive heart
failure and atrial fibrillation that underwent cura-
tive radiofrequency ablation for atrial fibrillation
demonstrated improvements in ejection fraction,
exercise capacity, and quality of life.7
THE MUTUAL PATHOPHYSIOLOGY
OF ATRIAL FIBRILLATION AND
LEFT VENTRICULAR DYSFUNCTION
Atrial fibrillation has significant hemodynamic
effects that are even more compromising to patients
with diminished cardiac function and compliance.
The loss of atrial kick in late diastole has long been
known to increase mitral and tricuspid regurgita-
tion, reduce diastolic filling and thus decrease car-
diac index. The irregularity of atrial fibrillation also
diminishes left ventricular filling time, further com-
promising cardiac output.8
Atrial natriuretic peptide, or ANP, is a peptide
released from atrial tissue in response to atrial pres-
sure overload or atrial stretch. This neurohormone
has significant vasodilator and diuretic properties
that may contribute to the lightheadedness and
diuresis when elevated in the presence of atrial fib-
rillation.9 With persistent or chronic atrial fibril-
lation, ANP levels decrease, allowing unopposed
activation of the renin–angiotensin axis, causing
further hemodynamic compromise.10 Tuinenburg
et al. evaluated the levels of several neurohormones
in 267 patients with sinus rhythm and atrial fibrilla-
tion.11 In patients with congestive heart failure and
atrial fibrillation there were significant increases in
plasma concentrations of ANP and the potent vaso-
constrictor, endothelin. The investigators found no
such increases in epinephrine, dopamine, renin,
and aldosterone levels.
Congestive heart failure exerts its own influence
on the initiation and sustainability of atrial fibrilla-
tion. Experimental models of congestive heart fail-
ure demonstrate a distinct cellular milieu compared
to tachycardia-induced atrial fibrillation. Li et al.
observed atrial hypertrophy in a canine model in
which heart failure was induced with prolonged
rapid ventricular pacing.12 In this model, there
were significant decreases in L-type calcium cur-
rent, transient outward potassium current, and
slowly rectifying potassium current.
There may also be an important role for atrial
stretch receptors in the development of atrial fibril-
lation. These nonspecific cation receptors respond
to passive stretch from elevated atrial pressure by
including rapid atrial tachycardias that can lead to
atrial fibrillation. Bode et al. used tarantula peptide
in a rabbit model to illustrate the importance of
these receptors. Atrial fibrillation inducibility and
duration steadily increased with increasing atrial
pressures in this model. When stretch receptors
were exposed to the peptide, initiation of atrial
fibrillation was completely suppressed even at the
highest atrial pressures used in the control group.13
THE ROLE OF CARDIAC
RESYNCHRONIZATION THERAPY
IN CONGESTIVE HEART FAILURE
Cardiac resynchronization is achieved by cor-
rection of electromechanical dyssynchrony caused
by a combination of left ventricular dilatation and
aberrant ventricular activation. This dysynchrony
is chiefly manifest by paradoxical septal motion
during systole that reduces stroke volume. All this
leads to diastolic mitral regurgitation, which fur-
ther exacerbates the vicious cycle of left ventricular
dilation and dysynchrony.
CRT corrects dysynchrony by producing a more
physiologic left ventricular activation sequence.
This is achieved by pacing the heart from two ven-
tricular sites: the right ventricular apex and the
lateral left ventricular wall. This, coupled with opti-
mization of the atrioventricular delay and interven-
tricular timing, increases diastolic filling time and
reduces paradoxical septal motion and diastolic mi-
tral regurgitation. Ultimately, this has been shown
to reduce left ventricular dimensions and improve
ejection fraction.
Early clinical trials showed improvements in ex-
ercise tolerance and quality of life.14 Recent larger
trials attempted to identify a survival benefit with
CRT. The COMPANION trail randomized 1520
patients to optimal medical therapy versus CRT
versus CRT with defibrillator capabilities (CRT-
D).15 Both CRT treatment groups achieved signif-
icant reductions in the combined primary end-
point of death or hospitalizations from heart failure.
Patients in the CRT-D group had a significant
34% reduction in all-cause mortality, while the CRT
group demonstrated a 24% reduction, approaching
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but not reaching statistical significance. The CARE-
HF study randomized 813 patients to medical ther-
apy or CRT pacing.16 Patients in the CRT group had
a 34% reduction in the primary endpoint of death
or cardiovascular events and significant reductions
in all-cause mortality. This was the first study to
show significant reductions in mortality from CRT
without support of an implantable defibrillator.
Permanent atrial fibrillation is especially bur-
densome to patients with congestive heart fail-
ure. Many of these patients are managed with a
strategy of rate control to reduce symptoms at-
tributed to accelerated ventricular rates. Unfor-
tunately, the negative inotropic effects of many
rate-controlling drugs limit their use. Ablation of
the atrioventricular node to maintain a regular
and controlled ventricular rate has been shown to
improve quality of life and exercise tolerance in
many patients. However, right ventricular pacing
causes dysynchronous left ventricular activation.
The clinical impact of this was demonstrated in the
DAVID trial, which evaluated 508 patients with im-
plantable defibrillators randomized to dual cham-
ber (DDD) pacing or back-up single chamber (VVI)
pacing at 40 beats per minute.17 In this trial, pa-
tients randomized to the back-up pacing mode had
significant reductions in the primary endpoint of
death or hospitalization. The study demonstrated
that chronic right ventricular pacing has detrimen-
tal effects on survival and heart failure hospitaliza-
tions in patients with left ventricular dysfunction.
The results of the DAVID trial are very rele-
vant to patients with left ventricular dysfunction
who have undergone ablation of the atrioventricu-
lar node for atrial fibrillation with rapid ventric-
ular rates, since they are pacemaker-dependent.
The role of CRT has been studied in several small
studies in this population. Leon et al. evaluated
20 consecutive patients with chronic atrial fibril-
lation and New York Heart Association Class III
heart failure who had undergone atrioventricular
nodal ablation for chronic atrial fibrillation.18 In
this study, there were significant improvements
in NYHA class, quality of life, ejection fraction,
and left ventricular dimensions after upgrade from
a right ventricular pacemaker to CRT. Garrigue
compared biventricular pacing with left ventri-
cular-only pacing and found similar benefits with
biventricular pacing over left ventricular pacing.19
A recent report compared outcomes of CRT in
patients with chronic atrial fibrillation and sinus
rhythm.20 In this study, 30 patients with a CRT de-
vice and sinus rhythm were compared to 30 pa-
tients treated with CRT who had permanent atrial
fibrillation. Both groups had comparable improve-
ments in left ventricular ejection fraction, 6-minute
walk and quality of life scores. Interestingly, half
of the atrial fibrillation patients had undergone atri-
oventricular nodal ablation, and their outcomes
were similar to the outcomes in patients who did
not have an ablation.
Since many of the early CRT trials excluded pa-
tients with atrial fibrillation, the role of cardiac
resynchronization therapy in reducing atrial fibril-
lation burden has yet to be explored. The hemo-
dynamic and autonomic benefits of CRT may cre-
ate a substrate with less atrial stretch and fewer
alterations in ion current density, thereby reduc-
ing atrial fibrillation. There are few case reports
citing examples of spontaneous restoration and
maintenance of sinus rhythm after treatment with
CRT.21,22 One trial is underway that is designed
to evaluate the efficacy of an algorithm to sup-
press atrial fibrillation incorporated into a CRT-D
device.23 The AF-CHF trial will randomize patients
to a rate control versus rhythm control strategy to
determine the best way to treat patients who have
cardiomyopathy and atrial fibrillation.24
In conclusion, the interplay between atrial fib-
rillation and congestive heart failure has deleteri-
ous effects. The use of CRT is gaining acceptance
for patients that are pacemaker-dependent in the
presence of spontaneous or intentional complete
heart block, in order to avoid the deleterious effects
of chronic right ventricular pacing. What is cur-
rently unknown is whether patients with conges-
tive heart failure and paroxysmal or persistent atrial
fibrillation can expect reductions in the arrhyth-
mia burden from the hemodynamic improvements
derived from CRT. Clinical trials that attempt
to address this specific question would be most
welcome.
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